<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Drug Development on FinanClub</title>
    <link>https://finan.club/tags/drug-development/</link>
    <description>Recent content in Drug Development on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 30 Jan 2024 09:06:25 +0000</lastBuildDate><atom:link href="https://finan.club/tags/drug-development/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Tue, 30 Jan 2024 09:06:25 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:76
Chances: Merck &amp;amp; Co., Inc. has been recognized for their strong performance and unwavering commitment to patients. With their estimated fair value of US$228 based on 2 Stage Free Cash Flow to Equity, there is potential for stock growth. KEYTRUDA has shown promising results in reducing the risk of death as adjuvant therapy for patients with RCC at an increased risk of recurrence following nephrectomy.</description>
    </item>
    
  </channel>
</rss>
